Molecular prognostic markers in pancreatic cancer

Cancer Control

Volumn 7, Issue 5, 2000, Pages 421-427

  Coppola, Domenico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CATHEPSIN; CELL RECEPTOR; CYCLOOXYGENASE 2; DNA; GROWTH FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; MESSENGER RNA; PROSTAGLANDIN; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BCL X; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

CARCINOGENESIS; CELL PROLIFERATION; CYTOGENETICS; HUMAN; ONCOGENE; PANCREAS CANCER; PLOIDY; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033805783     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480000700504     Document Type: Review

References (72)

1. The link between exocrine pancreatic cancer and the endocrine pancreas
2. Tumors of the pancreas
3. Epidemiology and etiology of pancreatic cancer
4. Nonrandom chromosomal rearrangements in pancreatic carcinomas
5. Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma
6. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
7. Relationship between DNA ploidy and survival in patients with exocrine pancreatic cancer
8. Expression of argyrophilic nucleolar organizer regions in ductal adenocarcinoma of the pancreas and its relationship to prognosis
9. Proliferating cell nuclear antigen (PCNA) in pancreatic adenocareinoma
10. Ki-67 and c-jun expression in pancreatic cancer: A prognostic marker?
11. Overexpression of p53 protein in adenocarcinoma of the pancreas
12. p53 Expression in human pancreatic cancer correlates with enhanced biological aggressiveness
13. p53 Protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis
14. Immunohistochemical analysis of p53 expression in human pancreatic carcinoma
15. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer
16. p53 Protein expression as prognostic factor in human pancreatic cancer
17. Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigarette smoking
18. 1 arrest
19. Analysis of p53,p21WAF1, and TGF-betal in human ductal adenocarcinoma of the pancreas: TGF-betal protein expression predicts longer survival
20. p53-Independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma
21. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism
22. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
23. Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy
24. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma
25. A tale of two src's: Mutatis mutandis
26. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells
27. Stat3 activation by Src induces specific gene regulation and is required for cell transformation
28. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
29. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer
30. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer
31. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs
32. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer
33. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
34. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth
35. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor
36. Transforming growth factor beta and cell cycle regulation
37. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1
38. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer
39. TGF-beta-1 up-regulates cyclin D1 expression in COLO-357 cells, whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor
40. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer
41. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
42. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells
43. Expression of CD44 variants and its association with survival in pancreatic cancer
44. Differential expression of CD44v6 in adenocarcinoma of the pancreas: An immunohistochemical study
45. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma
46. Tissue cathepsins as tumor markers
47. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression
48. High-affinity monomeric 67-kD laminin receptors and prognosis in pancreatic endocrine turnouts
49. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma
50. Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells
51. Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth
52. Mechanisms and functions of cell death
53. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation
54. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers
55. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer
56. Prognostic factors in resectable pancreatic cancer: p53 And bcl-2
57. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand
58. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells
59. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells
60. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
61. Cyclooxygenase2 gene expression is upregulated in transformed mammary epithelial cells
62. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
63. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
64. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
65. Expression of cyclooxygenase-2 in human gastric carcinoma
66. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
67. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
68. Recent advances in chemoprevention of cancer
69. Cyclooxygenase, NSAIDs, and colorectal cancer
70. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression